The density of CD10 corresponds to commitment and progression in the human B lymphoid lineage.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Cell Lineage* ; Lymphopoiesis*; Neprilysin/*immunology ; Precursor Cells, B-Lymphoid/*cytology ; Precursor Cells, B-Lymphoid/*immunology; Antigens, CD34/genetics ; Antigens, CD34/immunology ; Fetal Blood/cytology ; Fetal Blood/immunology ; Gene Expression ; Humans ; Neprilysin/genetics
    • Abstract:
      Background: Requirements for human B lymphopoiesis are still poorly understood, and that has hampered investigation of differentiation events. For example, there are few cell surface antigens that can be used as milestones of lineage progression. The CD10 ectoenzyme is one such marker and has been used to define CLP, but we found substantial tissue specific variations in CD10 levels, and there was no information about how that corresponded to differentiation options.
      Methodology/principal Findings: The aim of the present study was to use recently developed culture methods to assess the nature and differentiation potential of progenitors sorted according to CD10 density from umbilical cord blood (CB), adult bone marrow (BM) or G-CSF mobilized peripheral blood (PB). Many CD34(+) cells in BM express high levels of CD10, while low or low/negative CD10 densities were found on CD34(+) cells in CB or G-CSF mobilized PB, respectively. The relative abundance of CD10(Lo) versus CD10(Hi) cells only accounts for some CB versus BM differences. Almost all of the CD34(+) CD10(Hi) cells expressed CD19 and lymphocyte transcription factors and corresponded to loss of myeloid potential. A high degree of immunoglobulin D(H)-J(H) gene rearrangements was characteristic only of the CD10(Hi) subset. In contrast, the CD34(+) CD10(Lo) progenitors efficiently produced plasmacytoid and conventional dendritic cells as well as myeloid cells. These findings suggest a positive correlation between CD10 density and degree of differentiation. Although freshly isolated CD34(+) CD10(Hi) cells were in cycle, those from CB or BM expanded poorly in culture, suggesting regulators of populations remain to be discovered.
      Conclusions/significance: Steps in human B lymphopoiesis have not been sufficiently studied, and we now show that increased CD10 expression corresponds to differentiation potential and stage. CD34(+) CD10(Hi) progenitors are obviously in the B lineage but may have progressed beyond the point where they can be expanded in culture.
    • References:
      Trends Immunol. 2009 May;30(5):193-200. (PMID: 19356980)
      J Immunol. 1991 Nov 15;147(10):3324-30. (PMID: 1719075)
      J Immunol Methods. 2010 Jul 31;359(1-2):47-55. (PMID: 20540945)
      Eur J Immunol. 2005 Jul;35(7):2019-30. (PMID: 15971276)
      Leukemia. 2007 Feb;21(2):311-9. (PMID: 17170726)
      J Immunol. 2008 Jun 15;180(12):8109-17. (PMID: 18523275)
      N Engl J Med. 2004 Nov 25;351(22):2265-75. (PMID: 15564543)
      Blood. 2008 Nov 1;112(9):3753-61. (PMID: 18552210)
      Blood. 2002 Aug 15;100(4):1318-25. (PMID: 12149213)
      Blood. 2003 Jan 15;101(2):576-84. (PMID: 12393702)
      Int Immunol. 1992 Sep;4(9):1041-7. (PMID: 1390435)
      Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10348-53. (PMID: 8816803)
      J Immunol. 2007 Sep 15;179(6):3662-71. (PMID: 17785802)
      J Exp Med. 2007 Dec 24;204(13):3085-93. (PMID: 18070935)
      J Immunol. 2009 Apr 1;182(7):4255-66. (PMID: 19299724)
      Genes Dev. 2009 Oct 15;23(20):2376-81. (PMID: 19833765)
      Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5925-30. (PMID: 20231472)
      Blood. 2005 May 1;105(9):3488-92. (PMID: 15650059)
      Blood. 2008 Jun 15;111(12):5562-70. (PMID: 18424665)
      J Exp Med. 2006 Mar 20;203(3):675-87. (PMID: 16505143)
      In Silico Biol. 2005;5(1):45-60. (PMID: 15972004)
      Blood. 2004 Dec 15;104(13):3918-26. (PMID: 15331438)
      J Leukoc Biol. 2004 Feb;75(2):314-23. (PMID: 14634063)
      J Immunol. 2005 Dec 1;175(11):7325-31. (PMID: 16301638)
      Semin Hematol. 2002 Jan;39(1):3-14. (PMID: 11799524)
      Genes Dev. 1997 Mar 15;11(6):774-85. (PMID: 9087431)
      Cell. 1997 Nov 28;91(5):661-72. (PMID: 9393859)
      Eur J Immunol. 1998 Mar;28(3):855-64. (PMID: 9541580)
      Blood. 2001 May 1;97(9):2708-15. (PMID: 11313262)
      J Immunol. 2008 Dec 1;181(11):7514-24. (PMID: 19017941)
      Blood. 2003 May 1;101(9):3424-30. (PMID: 12446447)
      Br J Haematol. 2009 Apr;145(1):107-14. (PMID: 19183190)
      J Clin Oncol. 2009 Aug 1;27(22):3634-41. (PMID: 19581540)
      Exp Hematol. 2008 May;36(5):587-97. (PMID: 18346840)
      Immunity. 1995 Oct;3(4):459-73. (PMID: 7584137)
      J Allergy Clin Immunol. 2010 Apr;125(4):790-7. (PMID: 20371393)
      Annu Rev Immunol. 2004;22:625-55. (PMID: 15032591)
      J Immunol. 2005 Nov 1;175(9):5912-22. (PMID: 16237084)
      J Immunol. 1995 Jan 1;154(1):58-67. (PMID: 7527823)
      Blood. 2001 Jun 15;97(12):3683-90. (PMID: 11389003)
      Blood. 1997 Jun 1;89(11):3919-24. (PMID: 9166828)
    • Grant Information:
      R01 AI020069 United States AI NIAID NIH HHS; AI020069 United States AI NIAID NIH HHS
    • Accession Number:
      0 (Antigens, CD34)
      EC 3.4.24.11 (Neprilysin)
    • Publication Date:
      Date Created: 20101002 Date Completed: 20110218 Latest Revision: 20211020
    • Publication Date:
      20221213
    • Accession Number:
      PMC2944886
    • Accession Number:
      10.1371/journal.pone.0012954
    • Accession Number:
      20886092